Cell BT

Cell BT is a private immuno-oncology biotechnology company focused on discovering and developing innovative cancer therapeutics. Public disclosures describe the company as developing next-generation CAR-T antibody constructs against novel biological targets, with an initial focus on B-cell lymphomas, leukemias, and selected solid tumors. Historical company materials tie its scientific foundation to research from investigators at the Norris Comprehensive Cancer Center and the Keck School of Medicine of the University of Southern California. Limited recent public information is available on Cell BT as an operating company, and one program family using the "CBI" prefix, CBI-1214, is now publicly associated with Cartography Biosciences rather than Cell BT. Based on available evidence, Cell BT appears to have been a small private oncology biotech with early-stage assets and limited disclosed pipeline details.